Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Depakote ER is indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; FDA label
Also known as Divalproex Sodium Extended-Release Tablets, divalproex sodium extended release
Divalproex · 10 trials · 10 indications
| Name | Type | Description |
|---|---|---|
| Divalproex Sodium (Depakote Sprinkle Capsules) | DRUG | - |
| Divalproex Sodium (Depakote ER) | DRUG | - |
| divalproex sodium | DRUG | - |
| Divalproex Sodium Extended-Release Tablets | DRUG | - |
| divalproex sodium extended release | DRUG | - |
| Olanzapine | DRUG | - |
| Risperidone | DRUG | - |
Inclusion Criteria: Subject has diagnosis of partial seizures with/without secondary generalization, supported by: * Observed ictal events consistent with partial seizures with/without secondary generalization; Documented by reliable observers * 1 of following 3: * EEG at some time in past demo...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Divalproex is a small molecule drug developed by Abbott Laboratories, which trades under the ticker ABT. It is being studied in Phase 2 clinical trials for alcoholism, bipolar disorder, and schizophrenia. Divalproex is also known as divalproex sodium extended-release tablets. It is an investigational therapy in these psychiatric indications.
Divalproex targets ALDH5A1, also known as succinate-semialdehyde dehydrogenase. It acts as an inhibitor of this enzyme. This molecular target is involved in the metabolism of gamma-aminobutyric acid (GABA). By inhibiting ALDH5A1, divalproex may modulate GABAergic signaling, which is relevant to its studied psychiatric indications.
Divalproex is developed by Abbott Laboratories, a pharmaceutical company that trades on the New York Stock Exchange under the ticker symbol ABT. Abbott Laboratories is responsible for the clinical development of divalproex in the studied indications of alcoholism, bipolar disorder, and schizophrenia.
Divalproex is in Phase 2 clinical development. It has been tested in completed Phase 2 and Phase 3 trials for psychiatric conditions. The drug is investigational and has not been approved by the FDA for the studied indications. Abbott Laboratories is the developer.
Divalproex has been studied in completed clinical trials including NCT00202514, a Phase 2 placebo-controlled trial in alcohol-dependent patients with mood or anxiety symptoms; NCT00073164, a Phase 2 trial in schizophrenia; and NCT00067262, a Phase 3 trial in pediatric bipolar disorder. All trials were conducted in the United States.
Yes, divalproex is also known as divalproex sodium extended-release tablets, or divalproex sodium extended release. These names refer to the same medication developed by Abbott Laboratories. The extended-release formulation has been used in clinical trials for alcoholism, bipolar disorder, and schizophrenia.